Regeneron Pharmaceuticals, Inc. (BIT:1REGN)

Italy flag Italy · Delayed Price · Currency is EUR
480.90
0.00 (0.00%)
At close: Jul 18, 2025, 5:30 PM CET
Market Cap50.50B
Revenue (ttm)13.03B
Net Income (ttm)4.16B
Shares Outn/a
EPS (ttm)36.48
PE Ratio12.13
Forward PE14.61
Dividend0.84 (0.17%)
Ex-Dividend DateFeb 19, 2025
Volumen/a
Average Volume13
Open480.90
Previous Close480.90
Day's Range480.90 - 480.90
52-Week Range418.00 - 1,094.50
Betan/a
RSI57.70
Earnings DateAug 1, 2025

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]

Industry Pharmaceutical Preparations
Founded 1988
Employees 15,106
Stock Exchange Borsa Italiana
Ticker Symbol 1REGN
Full Company Profile

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial numbers in USD Financial Statements

News

There is no news available yet.